Alpidem

Title: Alpidem
CAS Registry Number: 82626-01-5
CAS Name: 6-Chloro-2-(4-chlorophenyl)-N,N-dipropylimidazo[1,2-a]pyridine-3-acetamide
Manufacturers' Codes: SL-80.0342
Trademarks: Ananxyl (Synthelabo)
Molecular Formula: C21H23Cl2N3O
Molecular Weight: 404.33
Percent Composition: C 62.38%, H 5.73%, Cl 17.54%, N 10.39%, O 3.96%
Literature References: Non-benzodiazepine tranquilizer. Prepn: J. P. Kaplan, P. George, EP 50563; eidem, US 4382938 (1982, 1983 both to Synthelabo). Pharmacology and pharmacokinetics in humans: B. Saletu et al., Int. Clin. Psychopharmacol. 1, 145 (1986). HPLC determn in human plasma: V. Ascalone et al., J. Chromatogr. 414, 101 (1987). Clinical evaluation of tranquilizing vs hypnotic effects: B. Saletu et al., Curr. Ther. Res. 40, 769 (1986). Pilot study in anxiety: S. F. Langer et al., Psychopharmacol. Bull. 24, 161 (1988). Hepatotoxicity in rats: A. Berson et al., J. Pharmacol. Exp. Ther. 299, 793 (2001).
Properties: mp 140-141°.
Melting point: mp 140-141°
Therap-Cat: Anxiolytic.
Keywords: Anxiolytic.
Status: This monograph has been retired and is no longer subject to revision or update.
Alpiropride Alprenolol Alsactide Alstonidine Alstonine

Alpidem
Alpidem.svg
Systematic (IUPAC) name
2-[3-chloro-8-(4-chlorophenyl)-1,7-diazabicyclo[4.3.0]nona-2,4,6,8-tetraen-9-yl]-N,N-dipropyl-acetamide
Clinical data
Legal status  ?
Routes Oral
Pharmacokinetic data
Excretion Renal
Identifiers
CAS number 82626-01-5
ATC code None
PubChem CID 54897
ChemSpider 49570 YesY
UNII I93SC245QZ YesY
KEGG D02833 YesY
ChEMBL CHEMBL54349 YesY
Chemical data
Formula C21H23Cl2N3O 
Mol. mass 404.332 g/mol
 YesY (what is this?)  (verify)

Alpidem (Ananxyl) is an anxiolytic drug from the imidazopyridine family, related to the more well known sleeping medication zolpidem. Unlike zolpidem however, alpidem does not produce sedative effects at normal doses, and is instead used specifically for the treatment of anxiety.[1][2]

Alipidem was developed by Synthélabo (now part of Sanofi-Aventis). It was approved for marketing in France in 1991. Clinical trial to obtain US FDA approval were halted in 1992 and the drug never received FDA approval. It was withdrawn from the French market by 1994 and is not approved for marketing anywhere in the world.[3]

Alpidem was known to act selectively on the α3 receptor subtype and to a lesser extent at the α1 subtype (Kd of 0.33nM and 1.67nM respectively), of the benzodiazepine receptor.[4][5] However the chemical structure of alpidem is not related to that of the benzodiazepines, and alpidem is thus sometimes referred to as a nonbenzodiazepine.[6]